Amylyx Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It focuses on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals Inc. is based in CAMBRIDGE, Mass.
Revenue (Most Recent Fiscal Year) | $380.79M |
Net Income (Most Recent Fiscal Year) | $49.27M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | 7.77 |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 0.29 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.36 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 2.86 |
Pre-Tax Margin (Trailing 12 Months) | -16.50% |
Net Margin (Trailing 12 Months) | -17.86% |
Return on Equity (Trailing 12 Months) | 4.14% |
Return on Assets (Trailing 12 Months) | 3.49% |
Current Ratio (Most Recent Fiscal Quarter) | 4.48 |
Quick Ratio (Most Recent Fiscal Quarter) | 4.48 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | 5.72 |
Book Value per Share (Most Recent Fiscal Quarter) | $6.42 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.46 |
Earnings per Share (Most Recent Fiscal Year) | $0.70 |
Diluted Earnings per Share (Trailing 12 Months) | $-1.07 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 68.01M |
Free Float | 60.05M |
Market Capitalization | $116.29M |
Average Volume (Last 20 Days) | 1.10M |
Beta (Past 60 Months) | -0.68 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 11.70% |
Percentage Held By Institutions (Latest 13F Reports) | 95.84% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |